

Pharmacokinetics of anti-tuberculosis drugs in multidrug resistant tuberculosis patients in India

Hemanth Kumar AK^{a*}, Natarajan PL^a, Kannan T^a, Sridhar R^b, Kumar S^b, Vinod Kumar V^b, Gomathi NS^a, Bharathiraja T^a, Sudha V^a, Balaji S^a, Rameshkumar S^a, Dina Nair^a, Tripathy SP^a, Geetha R^a

^a National Institute for Research in Tuberculosis, Chennai

^b Government hospital of Thoracic Medicine, Chennai

Running head: PK of anti-TB drugs in MDR TB

*Correspondence:

Dr. A K Hemanth Kumar

Scientist 'D' & Head

Department of Clinical Pharmacology

National Institute for Research in Tuberculosis

Mayor Sathyamoorthy Road

Chetpet, Chennai – 600 031

India

Ph.no: 91-44-28369650

Email: hemanthkumarak@nirt.res.in

Fax: 91-44-28362528

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Programmatic Management of multidrug resistant tuberculosis (MDR TB) services were introduced in the Indian TB control programme in 2007. A pharmacokinetic (PK) study of drugs used to treat MDR TB, namely levofloxacin (LFX), ethionamide (ETH), cycloserine (CS), pyrazinamide (PZA), moxifloxacin (MFX) and isoniazid (INH) was undertaken in adult MDR TB patients treated according to the prevailing guidelines in India. Factors influencing drug PK and end-of-intensive phase (IP) status were also determined. We recruited 350 MDR TB patients receiving anti-TB treatment (ATT) in the Indian Government programme in south India. At steady state, serial blood samples were collected, after supervised drug administration. Status at end of IP was noted from the programme records. Of the 303 patients for whom end-of-IP status was known, 214 were culture negative (responders), while 45 patients were either culture positive or required change of regimen or had died before completion of IP (non-responders). The median C_{max} (2.0 vs 2.9 μ g/ml; $p = 0.005$) and AUC_{0-12} (12.2 vs 17.0 μ g/ml.h; $p = 0.002$) of ETH were significantly lower in non-responders than responders at IP. In multivariate logistic regression analysis, after excluding defaulters and adjusting for confounders, AUC_{0-12} of ETH significantly influenced end-of-IP status (aOR - 1.065; 95% CI: 1.001 - 1.134; $p = 0.047$). Drug doses used currently in the programme produced optimal drug concentrations in majority of patients. ETH played a major role in the MDR TB combination regimen and was a key determinant of end-of-IP status.

Keywords: Multi-drug tuberculosis; Pharmacokinetics; anti-TB drugs; India

66 The burden of multidrug-resistant (MDR) tuberculosis (TB) is of major interest and concern at
67 global, regional and country levels. In 2018, there were approximately half a million (range 417000
68 – 556000) new cases of rifampicin-resistant (RR) TB, of which 78% had MDR TB (1). India
69 accounts for 27% of the total MDR TB cases worldwide, which is the highest for any country. This
70 is followed by China (14%) and the Russian federation (9%).

71 The National TB Elimination Programme (NTEP) in India had introduced Programmatic
72 Management of MDR TB (PMDT) services in 2007, and a complete geographic coverage was
73 achieved in 2013 (2). Under this programme, MDR TB patients were treated with six drugs which
74 included an aminoglycoside and a fluoroquinolone for a total period of 24 months. The intensive
75 phase (IP) of treatment was for 6 months comprising of kanamycin (Km), levofloxacin (LFX) ,
76 ethionamide (ETH), cycloserine (CS), pyrazinamide (PZA) and ethambutol (EMB) daily, followed
77 by the continuation phase of treatment for the remaining 18 months with LFX, Eth, CS and EMB
78 daily. If the 4th month culture for *M. tuberculosis* was positive, the intensive phase was extended
79 up to 9 months. Subsequently, in 2018, the regimens were revised and the duration of treatment
80 was shorter for a period of 9 months. In the revised regimen, the initial IP was for 4 months, during
81 which patients received Km, moxifloxacin (MFX), high dose isoniazid (INH), PZA, clofazimine
82 (CFZ), Eth and EMB daily. This was followed by the continuation phase for the remaining 5
83 months, during which patients received MFX, CFZ, PZA and EMB daily. In both regimens, drug
84 doses were based on body weight and were available in four weight bands, namely, 16 - 29 kg, 30
85 - 45 kg, 46 - 70 kg and > 70 kg (Table 1).

86 Cure rates observed among MDR TB patients from different studies varied from 31% to 75%, the
87 treatment regimens being different in these studies. A study from south India on the management
88 of MDR TB, reported a cure rate of 38%, with failure (25%), default (24%) and death (12%) (3).
89 The reasons for development of MDR TB could be due to microbial, clinical or programmatic
90 issues. Clinical characteristics of patients have also been recognized wherein appropriately
91 administered drug doses may not achieve necessary drug levels to deal with all populations of
92 mycobacteria. Maintaining therapeutic drug concentrations in blood is an important requisite to
93 achieve satisfactory treatment outcome. The National Jewish Medical and Research Centre at
94 Denver, CO, USA recommends measurement of serum concentrations of second-line anti-TB
95 drugs early in the course of treatment, so that poor drug absorption can be dealt with, in a timely
96 manner by optimizing drug doses (4).

97 A few studies have reported on the pharmacokinetics (PK) of second-line anti-TB drugs. A
98 population PK study in 14 MDR TB patients from Korea has been reported (5). Another study from
99 Tanzania has examined plasma activity of certain second-line anti-TB drugs in 25 patients with
100 MDR TB (6). Park and others from the Republic of Korea have described the PK of second-line
101 anti-TB medications in healthy volunteers (7). However, there is a paucity of PK data of second-

line anti-TB drugs in MDR TB patients from India. We undertook a prospective study to determine the PK of certain anti-TB drugs (LFX, MFX, Eth, CS, PZA, INH) in adult MDR TB patients in south India treated according to the prevailing NTEP guidelines. We also examined factors that influenced drug PK and culture status at end of IP.

Methods

Patients

A prospective study was undertaken in adult patients with MDR TB receiving anti-TB treatment (ATT) at the Government Hospital for Thoracic Medicine, Chennai, India during June 2016 to September 2019. All the patients were bacteriologically confirmed to have MDR TB based on drug susceptibility tests. Diagnosis and treatment were in accordance with the NTEP guidelines (2 - 3 of protocol). All the patients received drugs from the NTEP under direct supervision.

Patients meeting the following study criteria were recruited: (i) aged 18 years or above (ii) body weight > 30kg (iii) minimum seven doses of ATT drugs (iv) not very sick or moribund and (v) willing to participate and give informed written consent. A structured questionnaire was used to collect patient details. The study was approved by the Institutional Ethics Committee.

Study procedures

The PK study was conducted at the Government Hospital of Thoracic Medicine, Chennai, India after patients have had at least two weeks of treatment. Eligible patients were requested to get admitted to the hospital ward at least a day prior to start of the study. On the day of the study, a sample of blood (2 ml) was collected (pre-dosing). The prescribed anti-TB drugs were administered to the patients under supervision. Thereafter, serial blood samples were collected at 1, 2, 4, 6, 8 and 12 hours after drug administration. Those with a known history of type 2 diabetes mellitus (DM), with or without random blood glucose \geq 200mg/dl on the study day was considered diabetic. The patients' body mass index (BMI) was calculated from their height and body weight. A BMI below 18.5 was considered malnourished.

Drug estimations

Plasma concentrations of LFX, MFX, ETH, CS, INH and PZA were estimated by High Performance Liquid Chromatography (HPLC) (Shimadzu Corporation, Kyoto, Japan) according to validated methods described elsewhere. In brief, the method to estimate LFX and MFX involved deproteinisation of the sample with perchloric acid and analysis of the supernatant using a reversed-phase C18 column (150mm) using fluorescence detector set at an excitation wavelength of 290 nm and an emission wavelength of 460 nm. The mobile phase consisted of a mixture of phosphate buffer and acetonitrile. The retention times of LFX and MFX were 1.8 and 4.6 minutes respectively (8, 9).

135 Plasma INH and PZA were estimated simultaneously by extraction using para-
136 hydrobenzaldehyde and trifluoro acetic acid. Analysis was performed using a C₈ column at
137 267nm. The mobile phase consisted of water: methanol containing perchloric acid and tetrabutyl
138 n-ammonium hydroxide. The retention times of PZA and INH were 3 and 5.5 minutes respectively
139 (10).

140 The method for estimation of CS involved extraction of the drug using solid phase extraction
141 cartridges. The analytical column was Atlantis T3 and the mobile phase was a mixture of
142 phosphate buffer, acetonitrile and isopropyl alcohol. The retention time of CS was 4.8 minutes
143 (11).

144 The method for estimation of ETH involved deproteinisation of the sample with perchloric acid and
145 analysis of the supernatant using a reversed-phase CN column (150mm) and UV detector set at
146 267 nm. The mobile phase consisted of Milli-Q water and methanol containing 0.05% perchloric
147 acid and 0.1% tetrabutyl N-ammonium hydroxide. The retention time of ETH was 4.9 minutes (12).

148 **Calculation of Pharmacokinetic variables:** Based on plasma concentration of drugs at different
149 time-points, certain PK variables such as peak concentration (C_{max}), time at which C_{max} was
150 attained (T_{max}), area under the concentration-time curve (AUC_{0-12}) and half-life ($t_{1/2}$) were
151 calculated based on non-compartmental analysis using STATA 15.0 (StataCorp, College Station,
152 Texas, USA).

153 **Follow-up during treatment**

154 All patients continued to receive ATT according to NTEP guidelines. Culture results at end of
155 intensive phase, wherever available were recorded from the treatment card of patients. Based on
156 the culture status at end of IP, patients were divided into two groups - (i) those who were culture
157 negative (responders) and (ii) those who remained culture positive, those who had died during IP,
158 and those who required change in regimen (non-responders).

159 **Statistical Evaluation:** Data were analysed using STATA 15.0 (StataCorp, College Station,
160 Texas, USA). Shapiro-Wilks test was used to assess normality of the PK data. Values were
161 expressed as median and range. Non-parametric Mann-Whitney U test was used to compare
162 subgroups. Proportion of patients having C_{max} within the therapeutic ranges (8 - 13 μ g/ml for LFX;
163 20 - 60 μ g/ml for PZA; 2 - 5 μ g/ml for ETH; 20 - 35 μ g/ml for CS; 3 - 6 μ g/ml for INH 300/600mg; 9 -
164 15 μ g/ml for INH 900mg) (13) were calculated. Drug C_{max} and AUC_{0-12} were compared between
165 responders and non-responders to ATT. Multiple linear regression analysis by stepwise method
166 was carried out to identify factors that influenced C_{max} and AUC_{0-8} of drugs. Logistic regression
167 model was used to identify the association of C_{max} and AUC_{0-12} with culture negativity at the end of
168 IP. Some of the following factors such as age, gender, body weight, smoking status, alcoholism,
169 DM, culture and drug doses were considered in the regression model after considering the
170 variance inflation factor (VIF) and co-linearity. A $p \leq 0.05$ was considered statistically significant.

171

172

173 **Sample Size**

174 The sample size was calculated based on the study of Mpagama et al (6), who reported the peak
175 concentration of ETH to be 3.6µg/ml with the standard deviation of 1.8. Assuming a marginal error
176 of 20% and 10% refusal for blood draw, the sample size required was 346 patients.

177 **Results**

178 There were two groups of patients; those who were initially recruited received the LFX containing
179 regimen (Regimen 1) and subsequently when the programme revised the regimen, the patients
180 were being treated with the MFX-containing regimen (Regimen 2). A total of 350 patients took part
181 in the study, among whom 274 and 76 patients respectively received regimens 1 and 2. We
182 analysed combined data from both regimens and also performed regimen-wise analysis. We
183 present results obtained from the combined data. Details of all the patients recruited to the study
184 are shown in Table 2. Overall, patients with DM constituted 42% of the study population. About
185 62.3% of the patients had BMI <18.5kg/sq.m. A high proportion of patients were males (82.3%),
186 had pulmonary TB (97.1%) and were previously treatment with Category II ATT regimen (70.3%).

187 The PK parameters of LFX, ETH, CS, PZA, MFX, and INH are shown in Table 3. PK data was
188 available for 252, 259, 235, 300, 69, 63 patients for LFX, ETH, CS, PZA, MFX and INH
189 respectively. Missing values were mainly because patient had not taken a particular drug on the
190 study day or blood sample was not sufficient to undertake drug estimation. The median T_{max} was 2
191 hours for all the drugs tested in this study. The number of patients with C_{max} of LFX within the
192 therapeutic range (8 - 13µg/ml) was 126 (50%). The corresponding numbers for ETH (2 - 5µg/ml),
193 CS (20 - 35µg/ml), PZA (20 - 60µg/ml), MFX (3 - 5µg/ml), INH 300mg/600mg (3 - 6µg/ml), INH
194 900mg (9 - 15µg/ml) were 171 (66%), 83 (35.3%), 211 (70.3%), 22 (31.9%), 3 (7.5%) and 11
195 (47.8%) respectively. A high proportion of patients had C_{max} of CS (57.9%), MFX (58%) and INH
196 300mg/600mg (85%) above the upper limit of the therapeutic range. Those with sub-therapeutic
197 C_{max} ranged from 3.3% for PZA to 27.4% for ETH.

198 Drug C_{max} and AUC_{0-12} of the different groups of patients are shown in Tables 4 and 5 respectively.
199 Patients above 45 years of age had significantly higher C_{max} and AUC_{0-12} of LFX than those below
200 45 years (C_{max} : 12.0 vs 11.2µg/ml, $p = 0.041$; AUC_{0-12} : 94.7 vs 82.0µg/ml.h, $p = 0.004$). The AUC_{0-12}
201 of CS was significantly higher in male than female patients (354.8 vs 307.7, $p = 0.004$). The
202 C_{max} and AUC_{0-12} of LFX and CS were significantly higher in patients with BMI ≥ 18.5 than those
203 with BMI < 18.5. Patients with DM had significantly higher C_{max} of LFX (12.0 vs 11.1µg/ml; $p =$
204 0.014) and CS (42.4 vs 35.5µg/ml; $p = 0.004$) than those without DM. The AUC_{0-12} of CS was also

205 significantly higher in those with DM than those without DM (388.7 vs 323.9 $\mu\text{g/ml.h}$; $p = 0.004$).
206 Patients who consumed alcohol had higher C_{max} and AUC_{0-12} of CS, the difference attaining
207 statistical significance for AUC_{0-12} only (383.9 vs 323.4 $\mu\text{g/ml.h}$; $p = 0.017$). Non-responding
208 patients had significantly lower C_{max} (2.5 vs 2.9 $\mu\text{g/ml}$; $p = 0.040$) and AUC_{0-12} (14.4 vs 16.8 $\mu\text{g/ml.h}$;
209 $p = 0.034$) of ETH than responders at end of IP.

210 In multiple linear regression model, we determined factors that had an impact on C_{max} and AUC_{0-12}
211 of drugs. Using C_{max} as a dependent variable patients with $\text{BMI} > 18.5\text{kg/m}^2$ were likely to have 1.4
212 and 0.3 $\mu\text{g/ml}$ respectively of LFX and ETH C_{max} higher than those with $\text{BMI} < 18.5\text{kg/m}^2$. Patients
213 with culture positive *M. tuberculosis* were likely have 0.4 $\mu\text{g/ml}$ ETH C_{max} lower than those with
214 culture negative *M. tuberculosis*. An increase of one unit of drug dose taken was likely to cause
215 increases in the C_{max} of PZA, MFX and INH by 0.5 $\mu\text{g/ml}$, 0.3 $\mu\text{g/ml}$ and 0.7 $\mu\text{g/ml}$ respectively.

216 Using AUC_{0-12} as the dependent variable and adjusting for co-variates, age (LFX and ETH),
217 gender (CS), BMI (LFX, ETH and CS), alcoholism (ETH), culture status (ETH), and mg/kg drug
218 dose (ETH, PZA and MFX) were significant.

219 Of the 350 patients recruited to the study, status at end of IP were available for 303 patients in the
220 NTEP records. Among them, 214 were responders, while 45 patients were non-responders at end
221 of IP. Patients who had defaulted treatment ($n = 44$) were excluded from analysis. The median
222 C_{max} (2.0 vs 2.9 $\mu\text{g/ml}$; $p = 0.005$) and AUC_{0-12} (12.2 vs 17.0 $\mu\text{g/ml.h}$; $p = 0.002$) of ETH were
223 significantly lower in non-responders compared to responders (Figures 1A and B).

224 The influence of factors such as age, gender, body weight, smoking, alcohol use, DM and
225 $C_{\text{max}}/\text{AUC}_{0-12}$ of LFX, ETH, CS, PZA, MFX and INH on end of IP status were tested. After
226 excluding defaulters and adjusting for confounders, AUC_{0-12} of ETH was observed to significantly
227 influence end of IP status (aOR - 1.065; 95% CI: 1.001 - 1.134; $p = 0.047$). The chance of having
228 culture negativity at end of IP was higher by having AUC_{0-12} of ETH increased by 7% (Table 6).

229 Discussion

230 Effective control of MDR TB remains a challenge since second-line anti-TB medications are less
231 potent, may require longer treatment duration, have a narrow therapeutic range and have greater
232 number of side effects than first-line drugs (14). Hence treatment outcomes for MDR TB remain
233 sub-optimal compared to drug-susceptible TB. Furthermore, PK tools such as plasma drug
234 concentrations and MIC testing are not readily available in most TB endemic settings and it
235 remains unclear how such measurements are best utilised.

236 The importance of optimised drug exposure, leading to greater bacterial killing and better
237 outcomes has been shown in both murine models and human experience (15 - 17). In this
238 prospective cohort study, we have described the PK of anti-TB drugs used in the treatment of
239 MDR TB in India, and factors that were likely to influence status at end of IP. A higher proportion

240 of patients had C_{max} of LFX, ETH, PZA and INH 900mg within the therapeutic range. While this is
241 quite encouraging, we did observe a higher proportion of patients having C_{max} of CS, MFX, and
242 INH 300/600mg above the therapeutic range. The reason for higher proportion of patients who
243 received a relatively lower INH dose having C_{max} above the therapeutic range than those who
244 received a higher dose remains unclear, although patients' INH acetylator status would have
245 thrown some light on this issue. However, INH acetylator status was not determined in this study.
246 Our finding of 58% of patients having C_{max} of CS above the therapeutic range is in agreement with
247 that reported by Mpagama et al, which was 52% in their study (6). Using hollow fiber system
248 model of TB, Deshpande et al, determined the susceptibility breakpoint of CS, and reported that
249 drug doses required to achieve bacterial killing in patients was high, which was likely to cause
250 toxicity (18). In this study, we did not observe major adverse events due to CS at the time of the
251 PK sampling day. It should be pointed out that majority of the patients had their PK study
252 conducted within 4 weeks of treatment initiation. Psychosis as a side effect due to CS generally
253 shows up after a month of treatment; however, follow-up of patients beyond the PK study was not
254 part of this study. .

255 Our observation that a small proportion of patients only had sub-therapeutic C_{max} points to the fact
256 that drug doses used in the NTEP were quite adequate. A population PK study by Chigutsa and
257 others in South African MDR TB patients reported a high proportion of patients failed to achieve
258 the target ofloxacin exposure and suggested that LFX or MFX would be ideal fluoroquinolones to
259 treat MDR TB (19). According to the PMDT guidelines in India, LFX was part of the multi-drug
260 regimen and the revised shorter regimen had MFX in the place of LFX. Our observation of half of
261 the patients having optimal C_{max} of LFX contradicts the findings of Mpagama et al, who reported
262 LFX concentrations were frequently lower in MDR TB patients in Tanzania (6). Using nonlinear
263 mixed-effects modelling, a population PK study of PZA suggested 1500mg, 1750mg and 2000mg
264 PZA doses for MDR TB patients having weight bands upto 50kg, 51-70kg and above 70kg
265 respectively (20). The PZA doses followed in the NTEP are almost similar to that recommended in
266 the South African study.

267 A direct comparison of PK data of the drugs examined in this study could be compared with that
268 reported by others, since the Korean study was performed in healthy volunteers (7) and the
269 Tanzanian study examined drug concentrations only at 2 hours post-dosing (6). Furthermore,
270 these studies were conducted in small numbers, 14 healthy volunteers and 25 patients.

271 Patients above 45 years of age seemed to have higher C_{max} and AUC_{0-12} of LFX, probably due to
272 slower metabolism of the drug with aging. Female patients were observed to have higher
273 exposure of CS than their male counterparts. Although not many studies have reported gender -
274 based differences in second-line anti-TB medications, a similar trend has been observed with
275 respect to first-line anti-TB drugs (21 - 23). Our finding of patients with higher BMI having higher

276 C_{\max} and AUC_{0-12} of LFX and CS are not consistent with that reported with respect to first-line
277 drugs (20). Multivariate regression analysis also seemed to show BMI having a direct relationship
278 with drug concentrations. Likewise, higher LFX and CS concentrations observed in those with DM
279 than those without DM is also not in line with certain reports on RMP, INH and PZA (21, 24, 25).
280 While INH and PZA concentrations were lower in drug susceptible TB patients with DM than those
281 without DM (25, 26), no differences were observed in the case of MDR TB patients with and
282 without DM. It could be hypothesised that the metabolic pathways of drugs are different in patients
283 with drug susceptible and drug resistant TB, although the possibility of drug-drug interactions
284 cannot be ruled out. Nonetheless, this observation requires some attention and confirmation in
285 other studies.

286 The study showed that non-responding patients to ATT having lower C_{\max} and AUC_{0-12} of ETH than
287 responders is quite significant. We combined three different groups of patients as non-responders,
288 which included those who required a change of regimen. According to the NTEP, MDR TB
289 patients showing signs of clinical deterioration and becoming morbid have their treatment changed
290 to a bedaquiline - containing regimen. Thus, culture positives at end of IP, clinical failures and
291 deaths before completion of IP were combined and considered as non-responders. The PMDT
292 guidelines in India, recommends ETH as part of the MDR TB treatment regimen both initially and
293 in the revised regimen. Using a multidose hollow fiber system model, Deshpande et al,
294 demonstrated that ETH had a reasonable kill rate and that it was an important contributor to MDR
295 TB treatment regimens (27). Furthermore, suboptimal ETH exposure was likely to cause efflux
296 pump - mediated acquired drug resistance. Our study findings of C_{\max} and AUC_{0-12} of ETH being
297 higher in those who had culture conversion at end of IP than those who did not, and ETH
298 exposure emerging as a significant factor impacting end-of-IP status (after adjusting for
299 confounding factors and excluding defaulters) are consistent with the study of Deshpande and
300 others (27). In the light of these findings, it is crucial to include ETH as a part of the MDR TB
301 treatment regimen, and ensure that therapeutic concentrations of ETH are maintained.

302 In multivariate regression analysis, we demonstrated drug doses to have a significant influence on
303 the plasma concentrations of ETH, PZA, MFX and INH, and there was a direct relationship.
304 Increasing drug doses was likely to boost drug concentrations, although one needs to be cautious
305 about occurrence of toxic effects.

306 Our study findings are based on data analysed from all the 350 patients. We also performed
307 regimen-wise analysis. Of the drugs examined in this study, ETH and PZA were present in both
308 the regimens. No striking differences were observed in the PK profile of drugs in either regimen.
309 This observation was made with respect to patients maintaining therapeutic concentrations, group-
310 wise comparisons and factors influencing drug PK. It should however be added that the study was
311 not designed to examine drug-drug interactions, about which not much is known.

312 The strength of the study was the large sample size and understanding the association between
313 drug concentrations and patients' status at end of IP. The study was however, limited by the fact
314 that we did not follow up patients till end of treatment. Hence treatment outcomes and occurrence
315 of adverse reactions to drugs were not known. However, assessing end-of-treatment outcome in
316 MDR TB studies is quite cumbersome due to the long duration of treatment. Determination of INH
317 acetylator status could have provided additional information.

318 In summary, this is the first report describing the PK of second-line anti-TB drugs in MDR TB
319 patients in India. All patients were being treated according to the NTEP guidelines under direct
320 supervision, ensuring treatment regularity. The study conducted in a fairly large, adequately
321 powered sample size has demonstrated that the drug doses used currently in the programme
322 produced optimal drug concentrations in majority of patients. ETH played a major role in the MDR
323 TB combination regimen and was a key determinant of end-of-IP status. Future studies should
324 adopt a comprehensive approach assessing drug exposure, individual minimum inhibitory
325 concentrations and outcome. Researchers from China are aiming to conduct a translational study
326 that would characterise second-line anti-TB drug exposures and relate them to individual MICs
327 (28). It is important to carry out similar PK/PD studies in different parts of India, in order to
328 generalise the findings.

329 **Acknowledgements**

330 The authors thank the patients who took part in the study, A Vijayakumar for drug estimations by
331 HPLC, clinic nurses of NIRT for blood collections, and secretarial assistance by S. Sasikumar.

333 **Authors' contributions**

334 AKH and GR designed the study, AKH wrote the study protocol and obtained regulatory
335 approvals, RS, PLN, SRK, DN and SK supervised patient recruitment, PLN and TB conducted the
336 study, AKH supervised drug estimations, VS and TB performed drug estimations, NSG and AB
337 supervised bacteriological investigations, TK performed statistical analysis and GR drafted the
338 manuscript.

340 **Potential conflict of interest:** None

346

347

348

349

350

351

References

352

1. Global TB report, 2019. Available at: http://www.who.int/tb/publications/global_report/en/

353

2. RNTCP Guidelines for Programmatic Management of Drug Resistant Tuberculosis (PMDT) in India, 2012. Available at: <https://tbcindia.gov.in>

354

355

3. Thomas A, Ramachandran R, Rehman F, Jaggarajamma K, Santha T, Selvakumar N, Krishnan N, Nalini SM, Sundaram V, Fraser W, Narayanan PR. Management of multi-drug resistant tuberculosis in the field - Tuberculosis Research Centre experience. *Indian J Tub* 2007; 54: 117-124

356

357

358

359

4. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. *Drugs* 2002; 62: 2169–2183

360

361

5. Chang MJ, Jin B, Chae J, Yun H, Kim ES, Lee YJ, Cho YJ, Yoon HI, Lee CT, Park KU, Song J, Lee JH, Park JS. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. *Int J Antimicrob Agents* 2017; 49 : 677-687. doi: 10.1016/j.ijantimicag.2017.01.024

362

363

364

365

6. Mpagama SG, Ndusilo N, Stroup S, Kumburu H, Peloquin CA, Gratz J, Houpt ER, Kibiki GS, Heysell SK. Plasma drug activity in patients on treatment for multi-drug resistant tuberculosis. *Antimicrob Agents Chemother*. 2014;58:782- 788. doi: 10.1128/AAC.01549-13

366

367

368

7. Park S, Oh J, Jang K, Yoon J, Moon SJ, Park SJ, Lee JH, Song J, Jang IJ, Yu KS, Chung JY. Pharmacokinetics of second-line antituberculosis drugs after multiple administrations in healthy volunteers. *Antimicrob Agents Chemother* 2015; 59: 4429 – 4435. doi: 10.1128/AAC.00354-15

369

370

371

372

8. Hemanth Kumar AK, Sudha V, Ramachandran G. A Simple and Rapid Liquid Chromatography method for determination of Levofloxacin in Plasma. *SAARC J TB, Lung Diseases & HIV/AIDS*, 2016; XIII: 28 - 33

373

374

375

9. Hemanth Kumar AK, Geetha Ramachandran. Simple and rapid liquid chromatography method for determination of moxifloxacin in plasma. *J Chromatogr B Analyt Technol Biomed Life Sci*, 2009; 877: 1205-1208. doi: 10.1016/j.jchromb.2009.02.042

376

377

378

10. Hemanth Kumar AK, Sudha V, Geetha Ramachandran. Simple and rapid liquid chromatography method for simultaneous determination of isoniazid and pyrazinamide in

379

- 380 plasma. SAARC J TB, Lung diseases & HIV/AIDS 2012; 9: 13 – 18.
381 DOI: <https://doi.org/10.3126/saarctb.v9i1.6960>
- 382 11. Hemanth Kumar AK, Polisetty AK, Sudha V, Vijayakumar A, Geetha Ramachandran. A
383 Selective and sensitive high performance liquid chromatography assay for the
384 determination of cycloserine in human plasma. *Ind J Tub* 2018; 65: 118 – 123.
385 doi: 10.1128/AAC.02410-17
- 386 12. Hemanth Kumar AK, Sudha V, Geetha Ramachandran. Simple and rapid high pressure
387 liquid chromatography methods for estimation of ethionamide in plasma. *Asian J Biomed*
388 *Pharmaceut Sci* 2014; 04: 1 - 5
- 389 13. Abdullah A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an
390 update. *Drugs* 2014; 74: 839-854. doi: 10.1007/s40265-014-0222-8
- 391 14. Sheno S, Heysell SK, Moll A, Friedland G. Multidrug-resistant and extensively drug-
392 resistant tuberculosis: consequences for the global HIV community. *Curr Opin Infect*
393 *Dis* 2009; 22:11–17. 10.1097/QCO.0b013e3283210020. doi:
394 10.1097/QCO.0b013e3283210020
- 395 15. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA,
396 Neurmberger EL, Grosset JH. Treatment of tuberculosis with rifamycin containing
397 regimens in immune-deficient mice. *Am J Respir Crit Care Med* 2011; 183:1254 – 1261.
398 10.1164/rccm.201012-1949OC
- 399 16. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month
400 regimens and relapse for pulmonary tuberculosis. *Am J Respir Crit Care Med* 2006;
401 174:1153 –1158. 10.1164/rccm.200605-637OC
- 402 17. Egelund EF, Peloquin CA. Pharmacokinetic variability and tuberculosis treatment
403 outcomes, including acquired drug resistance. *Clin Infect Dis* 2012; 55:178–179.
404 10.1093/cid/cis366
- 405 18. Devyani D, Alffenaar JW, Kose CU, Dheda K, Chapagain ML, Simbar N, Schon T,
406 Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S,
407 Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T. D-Cycloserine
408 Pharmacokinetics/Pharmacodynamics susceptibility and dosing implications in multidrug-
409 resistant tuberculosis: A Faustian deal. *Clin Infect Dis* 2018; 67: S308-316. doi:
410 10.1093/cid/ciy624
- 411 19. Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, Moodley P, Mac Kenzie WR,
412 Weiner M, McIlleron H, Kirkpatrick CMJ. Population pharmacokinetics of ofloxacin in South
413 African patients with multi-drug resistant tuberculosis. *Antimicrob Agents Chemother* 2012;
414 56: 3857-3863. doi: 10.1128/AAC.00048-12
- 415 20. Chirehwa MT, McIlleron H, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, Denti P.
416 Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-sensitive and

- 417 resistant tuberculosis. *Antimicrob Agents Chemother.* 2017;61:1-11. doi:
418 10.1128/AAC.00490-17
- 419 21. A K Hemanth Kumar, T Kannan, V Chandrasekaran, V Sudha, A Vijayakumar, K Ramesh,
420 J Lavanya, Soumya Swaminathan, Geetha Ramachandran. Pharmacokinetics of thrice
421 weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. *Int J*
422 *Tuberc Lung Dis* 2016; 20:1236-1241. doi: 10.5588/ijtld.16.0048
- 423 22. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin,
424 isoniazid, pyrazinamide and ethambutol pharmacokinetics in a cohort of tuberculosis
425 patients. *Antimicrob Agents Chemother* 2006; 50: 1170 – 1177
- 426 23. Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by therapeutic drug
427 monitoring of rifampicin and isoniazid. *Intern Med J* 2003; 33:229 – 234
- 428 24. Nijland HM, Ruslami JR, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, van der
429 Ven JAM, Danusantoso H, Aarnoutse RE, van Crevel R. Exposure of Rifampin is strongly
430 reduced in tuberculosis patients with type 2 diabetes. *Clin Infect Dis* 2006; 43: 848 – 854
- 431 25. Hemanth Kumar AK, Chandrasekaran V, Kannan T, Lakshmi Murali, Lavanya J, Sudha V,
432 Soumya Swaminathan, Geetha Ramachandran. Anti-tuberculosis drug concentrations in
433 tuberculosis patients with and without diabetes mellitus. *Eur J Clin Pharmacol* 2017; 73: 65
434 – 70. doi: 10.1007/s00228-016-2132-z
- 435 26. Babalik A, Ulus IH, Bakirci N, Kuyucu T, Arpag H, Dagyildizi L, Capaner E. Plasma
436 Concentrations of Isoniazid and Rifampin are decreased in adult pulmonary tuberculosis
437 patients with diabetes mellitus. *Antimicrob Agents Chemother.* 2013; 5740 – 5742. doi:
438 10.1128/AAC.01345-13
- 439 27. Deshpande D, Pasipanodya JG, Mpagama SG, Srivastava S, Bendet P, Koeuth T, Lee PS,
440 Heysell SK, Gumbo T. Ethionamide Pharmacokinetics/Pharmacodynamics- derived dose,
441 the role of MICs in clinical outcome, and the resistance arrow of time in multidrug-resistant
442 tuberculosis. *Clin Infect Dis* 2018; 67 :S317-326. doi: 10.1093/cid/ciy609
- 443 28. Forsman LD, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y,
444 Werngren J, Paues J, Kuhlín J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjo M,
445 Hoffner S, Xu B, Schon T, Brushfeld J. Plasma concentrations of second-line anti-
446 tuberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant
447 tuberculosis patients in China: a study protocol of a prospective observational cohort study.
448 *BMJ Open* 2018; 4;8:e023899. doi: 10.1136/bmjopen-2018-023899

449

450

451

452
453
454
455
456
457
458
459
460
461
462
463

Table 1: Drug doses and weight bands followed in the PMDT guidelines

INTENSIVE PHASE (6 MONTHS)				
DRUGS	16 - 29 kg	30 - 45 kg	46 - 70 kg	ABOVE 70 kg
LFX	250	750	1000	1000
ETH	375	500	750	1000
CS	250	500	750	1000
EMB	400	800	1200	1600
PZA	750	1250	1750	2000
KM	500	750	750	1000
CONTINUATION PHASE (18 MONTHS)				
DRUGS	16 - 29 kg	30 - 45 kg	46 - 70 kg	ABOVE 70 kg
LFX	250	750	1000	1000
ETH	375	500	750	1000
CS	250	500	750	1000
EMB	400	800	1200	1600
MDR SHORTER REGIMEN				
INTENSIVE PHASE (4 - 6 MONTHS)				
DRUGS	16 - 29 kg	30 - 45 kg	46 - 70 kg	ABOVE 70 kg
HIGH DOSE MFX	400	600	800	800
HIGH DOSE INH	300	600	900	900
PZA	750	1250	1750	2000
ETH	375	500	750	1000
CFZ	50	100	100	200
EMB	400	800	1200	1600

464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481

KM	500	750	750	1000
CONTINUATION PHASE (5 MONTHS)				
DRUGS	16 - 29 kg	30 - 45 kg	46 - 70 kg	ABOVE 70 kg
MFX	400	600	800	800
CFZ	50	100	100	200
PZA	750	1250	1750	2000
EMB	400	800	1200	1600

LFX - Levofloxacin; ETH - Ethionamide; CS - Cycloserine; EMB - Ethambutol; PZA - Pyrazinamide; KM - Kanamycin

Table 2: Patient Details (n = 350)

Parameters	n (%)
Age, years, Median (IQR)	45 (34 - 55)
Gender	
Female	62 (17.7%)
Male	288 (82.3%)
BMI, kg/m², Median (IQR)	
<18.5	218 (62.3%)
≥ 18.5	132 (37.7%)
Diabetes	
No	203 (58.0%)
Yes	147 (42.0%)
Smoking Status	
No	249 (71.1%)
Yes	101 (28.9%)
Alcoholism	
No	236 (67.4%)
Yes	114 (32.6%)
Type of TB	
Extra Pulmonary TB	10 (2.9%)

Parameters	n (%)
Pulmonary TB	340 (97.1%)
Past History of TB	
No	31 (8.9%)
Yes	319 (91.1%)
Category of ATT	
Category I	49 (14.0%)
Category II	246 (70.3%)
Others	55 (15.7%)
Smear Status	
Negative	105 (30.0%)
Positive	245 (70.0%)
Culture Status	
Negative	110 (31.4%)
Positive	240 (68.6%)
Biochemical Parameters	
Haemoglobin (g/dl)	11.8 (10.5 - 13.4)
Glucose (mg/dl)	127 (98.5 - 231.5)
Creatinine (mg/dl)	0.9 (0.7 - 1.0)
Alanine Pyruvate Transaminase (U/L)	25 (20 - 29)
Dose mg/kg body weight	
Moxifloxacin	15.0 (13.0 - 16.2)
Levofloxacin	18.8 (17.4 - 20.8)
Ethionamide	13.5 (12.5 - 15.0)
Cycloserine	13.6 (12.5 - 15.0)
Isoniazid	15.4 (13.8 - 17.3)
Pyrazinamide	30.0 (27.8 - 33.0)
Ethambutol	21.6 (19.7 - 24.0)

Table 3: Pharmacokinetic parameters of drugs
(Values are given as Median & Inter quartile range)

PK Parameters	Levofloxacin n = 252	Ethionamide n = 259	Cycloserine n = 235	Pyrazinamide n = 300	Moxifloxacin n = 69	Isoniazid (300/600mg dose) n = 40	Isoniazid (900mg dose) n = 23
C _{max} , µg/ml	11.6 (9.3 - 14.4)	2.5 (2.0 - 2.5)	37.5 (28.3 - 47.9)	48.9 (38.7 - 60.3)	5.6 (3.9 - 8.1)	10.5 (7.8 - 15.9)	11.8 (7.2 - 19.5)
T _{max} , h	2 (1 - 4)	2 (2 - 2)	2 (2 - 4)	2 (2 - 4)	2 (2 - 4)	2 (1 - 2)	2 (1 - 2)
AUC ₀₋₁₂ , µg/ml.h	88.6 (69.7 - 111.4)	15.2 (10.5 - 15.2)	344.3 (263.8 - 454.6)	453.9 (336.4 - 576.6)	43.1 (30.1 - 64.9)	58.3 (40.0 - 102.4)	74.6 (36.7 - 113.1)
T _{1/2} , h	8.0 (6.2 - 11.2)	3.4 (2.2 - 3.4)	16.3 (11.6 - 24.1)	12.7 (9.6 - 16.8)	7.0 (5.7 - 8.8)	4.8 (3.6 - 6.3)	4.7 (3.5 - 6.6)
No (%) of Patients with C_{max}							
Below therapeutic Range	34 (13.5%)	71 (27.4%)	16 (6.8%)	10 (3.3%)	7 (10.1%)	3 (7.5%)	6 (26.1%)
Within therapeutic Range	126 (50.0%)	171 (66.0%)	83 (35.3%)	211 (70.3%)	22 (31.9%)	3 (7.5%)	11 (47.8%)
Above therapeutic Range	92 (36.5%)	17 (6.6%)	136 (57.9%)	79 (26.3%)	40 (58.0%)	34 (85.0%)	6 (26.1%)

483

484 Therapeutic Range: LFX: 8 – 13 µg/ml; ETH: 2 – 5 µg/ml; CS: 20 – 35 µg/ml; PZA: 20 – 60 µg/ml; MFX: 3 – 5 µg/ml; INH: 3 – 6 µg/ml; C_{max} = Peak

485 Concentration; T_{max} = Time at which peak concentration was attained; AUC = area under the time concentration curve; T_{1/2} = half-life

486

487

488

Table 4: C_{max} of drugs among different patient groups

Parameters	Levofloxacin (µg/ml)		Ethionamide (µg/ml)		Cycloserine (µg/ml)		Pyrazinamide (µg/ml)		Moxifloxacin (µg/ml)		Isoniazid (µg/ml)	
	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)
Age, years												
<45	128	11.2 (9.1 - 13.7)	121	2.4 (1.9 - 3.4)	120	37.0(28.3 - 45.4)	140	50.6 (39.4 - 59.8)	26	5.1 (3.6 - 7.4)	25	9.9 (7.8 - 14.2)
≥45	124	12.0 (9.6 - 15.9)	138	2.7 (2.0 - 3.8)	115	38.5 (28.3 - 48.7)	160	47.9 (37.8 - 60.5)	43	5.7 (4.1 - 8.1)	38	13.1 (7.9 - 16.9)
P Value		0.041		0.151		0.222		0.791		0.396		0.232
Gender												
Female	38	11.6 (9.3 - 15.1)	37	2.5 (1.9 - 3.9)	34	33.6 (26.5 - 40.6)	57	52.1 (41.1 - 59.6)	20	5.2 (3.9 - 7.0)	18	11.5 (7.5 - 16.1)
Male	214	11.6 (9.4 - 14.3)	222	2.6 (2.0 - 3.6)	201	37.9 (29.2 - 48.1)	243	48.6 (38.2 - 60.5)	49	5.7 (3.9 - 8.1)	45	11.1 (7.9 - 15.7)
P Value		0.759		>0.99		0.071		0.802		0.832		0.796
BMI, kg/m²												
<18.5	157	11.2 (8.7 - 13.7)	151	2.5 (1.8 - 3.5)	147	36.2 (27.5 - 46.1)	184	47.9 (38.3 - 60.9)	41	6.1 (4.1 - 8)	41	11.1 (7.8 - 15.7)
≥18.5	95	12.2 (10.9 - 15.1)	108	2.6 (2.1 - 3.9)	88	42.5 (31.6 - 48.4)	116	50.1 (39.5 - 60.0)	28	5.0 (3.5 - 8.2)	22	10.7 (8.0 - 19.5)
P Value		0.004		0.051		0.025		0.977		0.396		0.806
Smoking Status												
No	177	11.6 (9.4 - 13.8)	182	2.5 (2.0 - 3.6)	167	37.2 (27.5 - 48.6)	214	50.9 (38.2 - 60.2)	52	5.5 (3.9 - 7.8)	48	11 (7.6 - 16.3)
Yes	75	11.6 (8.7 - 15.6)	77	2.8 (2.0 - 3.9)	68	38.9 (30.8 - 47.5)	86	47.7 (39.5 - 61.3)	17	5.7 (4.3 - 8.2)	15	12.4 (7.9 - 14.6)
P Value		0.814		0.611		0.406		0.960		0.723		0.987
Alcoholism												
No	166	11.4 (9.4 - 13.8)	171	2.5 (1.9 - 3.6)	153	36.2 (27.3 - 46.1)	200	50.4 (37.8 - 60.1)	50	5.6 (3.9 - 8.2)	46	10.9 (7.2 - 16.6)
Yes	86	11.8 (8.9 - 15.6)	88	2.9 (2.0 - 3.9)	82	39.7 (31.2 - 48.3)	100	48.0 (39.4 - 62.2)	19	5.6 (3.8 - 8.0)	17	12.4 (9.1 - 14.3)
P Value		0.419		0.258		0.055		0.879		0.523		0.733
Diabetes												
No	141	11.1 (9.0 - 13.7)	147	2.5 (2.0 - 3.6)	134	35.5 (27.4 - 45.1)	172	50.7 (39.3 - 60.4)	43	5.6 (4.0 - 8.0)	43	12.4 (7.8 - 16.1)
Yes	111	12.0 (10.0 - 15.1)	112	2.6 (1.9 - 3.9)	101	42.4 (31.2 - 49.4)	128	48.0 (37.8 - 60.3)	26	5.6 (3.9 - 8.2)	20	9.6 (6.4 - 17.3)
P Value		0.014		0.891		0.004		0.683		0.911		0.516
Culture Status												
Negative	59	11.6 (9.1 - 14.6)	84	2.9 (2.0 - 3.8)	52	37.1 (27.2 - 46.0)	96	50.1 (40.0 - 58.9)	39	5.4 (3.9 - 8.2)	35	13.6 (8.5 - 16.1)
Positive	193	11.5 (9.4 - 14.3)	175	2.5 (1.9 - 3.6)	183	37.6 (29.2 - 48.3)	204	48.7 (37.4 - 60.5)	30	5.7 (4.0 - 8.0)	28	9.5 (6.6 - 15.8)
P Value		0.857		0.040		0.525		0.854		0.785		0.125

491
492

Table 5: AUC₀₋₁₂ of drugs among different patient groups

Parameters	Levofloxacin (µg/ml)		Ethionamide (µg/ml)		Cycloserine (µg/ml)		Pyrazinamide (µg/ml)		Moxifloxacin (µg/ml)		Isoniazid (µg/ml)	
	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)	n	Median (IQR)
Age, years												
<45	128	82.0 (67.0 - 105.2)	121	13.6 (10.0 - 20.4)	120	329.6 (260.6 - 436.1)	140	458.0 (336.4 - 560.3)	26	38.2 (27.1 - 60.3)	25	58.0 (40.6 - 83.8)
≥45	124	94.7 (73.6 - 119.6)	138	15.9 (11.3 - 21.8)	115	353.3 (266.6 - 466.2)	160	448.1 (335.4 - 605.0)	43	44.7 (32.1 - 69.9)	38	75.7 (39.7 - 112.4)
P Value	0.004		0.076		0.117		0.637		0.373		0.232	
Gender												
Female	38	82.1 (61.5 - 103.8)	37	13.4 (10.0 - 21.1)	34	307.7 (227.1 - 392.3)	57	423.2 (313.1 - 552.2)	20	36.7 (30.4 - 53.0)	18	66.4 (43.4 - 102.3)
Male	214	89.9 (70.3 - 113.0)	222	15.4 (11.3 - 20.8)	201	354.8 (267.0 - 460.1)	243	454.7 (339.1 - 594.2)	49	47.9 (30.1 - 69.9)	45	65.2 (39.7 - 102.4)
P Value	0.134		0.716		0.004		0.269		0.308		0.704	
BMI, kg/m²												
<18.5	157	85.2 (66.0 - 108.9)	151	13.7 (9.9 - 20.3)	147	322.7 (260.2 - 447.7)	184	443.7 (335.2 - 591.3)	41	49.3 (32.4 - 64.2)	41	63.9 (39.7 - 97.1)
≥18.5	95	94.3 (75.8 - 112.9)	108	15.7 (11.7 - 21.9)	88	401.6 (296.6 - 457.4)	116	468.4 (336.9 - 568.9)	28	36.7 (29.1 - 67.4)	22	75.4 (40.6 - 113.1)
P Value	0.048		0.060		0.015		0.629		0.406		0.395	
Smoking Status												
No	177	87.8 (69.8 - 112.9)	182	15.2 (10.4 - 21.1)	167	333.1 (258.2 - 454.6)	214	451.5 (333.9 - 573.7)	52	42.0 (29.8 - 62.3)	48	64.8 (40.0 - 104.1)
Yes	75	90.7 (68.9 - 111.4)	77	15.4 (11.3 - 20.4)	68	369.5 (287.7 - 453.5)	86	454.9 (341.8 - 594.2)	17	44.7 (32.1 - 71.3)	15	65.2 (39.7 - 97.1)
P Value	0.579		0.905		0.218		0.671		0.568		0.910	
Alcoholism												
No	166	87.5 (67.4 - 111.3)	171	14.4 (10.0 - 20.8)	153	323.4 (251.3 - 446.8)	200	457.5 (332.2 - 574.2)	50	42.0 (30.1 - 64.9)	46	64.8 (36.7 - 103.8)
Yes	86	90.8 (70.6 - 117.6)	88	17.6 (11.5 - 21.4)	82	383.9 (302.6 - 466.2)	100	451.0 (347.0 - 580.0)	19	43.5 (29.4 - 66.8)	17	65.2 (40.6 - 85.2)
P Value	0.321		0.226		0.017		0.754		0.747		0.865	
Diabetes												
No	141	84.3 (65.6 - 108.9)	147	14.1 (10.8 - 21.4)	134	323.9 (251.2 - 430.4)	172	460.6 (339.9 - 583.4)	43	43.1 (31.6 - 64.2)	43	73.3 (39.7 - 102.4)
Yes	111	93.8 (75.8 - 112.9)	112	15.5 (10.4 - 20.4)	101	388.7 (300.5 - 466.2)	128	449.5 (333.6 - 571.6)	26	42.3 (29.5 - 69.8)	20	56.2 (38.7 - 107.7)
P Value	0.183		0.989		0.004		0.635		0.862		0.690	
Culture Status												
Negative	59	87.1 (67.0 - 114.5)	84	16.8 (11.4 - 23.0)	52	337.6 (238.6 - 437.1)	96	453.9 (336.9 - 560.6)	39	41.1 (29.4 - 64.9)	35	78.2 (48.3 - 104.3)
Positive	193	89.4 (70.3 - 109.0)	175	14.4 (10.0 - 20.2)	183	348.8 (264.1 - 459.1)	204	454.1 (335.6 - 591.9)	30	43.3 (32.4 - 66.8)	28	49.9 (36.8 - 82.0)
P Value	0.933		0.034		0.250		0.933		0.654		0.638	

493


Table 6: Impact of drug levels on status at end of intensive phase

Drug	Peak Concentration				Exposure			
	OR (95% CI)	P Value	aOR (95% CI)	P Value	OR (95% CI)	P Value	aOR (95% CI)	P Value
LFX	0.993 (0.915 - 1.078)	0.872	1.001 (0.919 - 1.090)	>0.950	0.999 (0.990 - 1.008)	0.802	0.999 (0.990 - 1.009)	0.875
ETH	1.321 (0.931 - 1.874)	0.118	1.262 (0.885 - 1.799)	0.198	1.068 (1.005 - 1.136)	0.034	1.065 (1.001 - 1.134)	0.047
CS	1.014 (0.986 - 1.043)	0.332	1.010 (0.981 - 1.041)	0.503	1.002 (0.999 - 1.004)	0.273	1.001 (0.998 - 1.004)	0.498
PZA	0.992 (0.972 - 1.012)	0.429	0.993 (0.974 - 1.014)	0.523	0.999 (0.997 - 1.001)	0.509	0.999 (0.997 - 1.001)	0.523
INH	0.974 (0.828 - 1.144)	0.745	0.960 (0.799 - 1.240)	0.814	1.000 (0.974 - 1.026)	>0.950	1.043 (0.980 - 1.040)	0.912
MFX	0.821 (0.557 - 1.210)	0.318	0.880 (0.520 - 1.490)	0.451	0.976 (0.930 - 1.025)	0.333	0.990 (0.910 - 1.240)	0.512

Odds ratio was calculated after adjusting for the factors such as age, gender, body weight, smoking status, alcoholism and diabetes mellitus

498 **Figure 1: Boxplot (Median & IQR) comparing C_{max} (A) and AUC_{0-12} (B) of drugs between responders and non-responders**

499 **A**



*Statistically significant ($p=0.005$)

■ Non-responders □ Responders

500

501

